Literature DB >> 22844983

Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.

Jochen Schmitt1, Phyllis Spuls, Maarten Boers, Kim Thomas, Joanne Chalmers, Evelien Roekevisch, Mandy Schram, Richard Allsopp, Valeria Aoki, Christian Apfelbacher, Carla Bruijnzeel-Koomen, Marjolein Bruin-Weller, Carolyn Charman, Arnon Cohen, Magdalene Dohil, Carsten Flohr, Masutaka Furue, Uwe Gieler, Lotty Hooft, Rosemary Humphreys, Henrique Akira Ishii, Ichiro Katayama, Willem Kouwenhoven, Sinéad Langan, Sue Lewis-Jones, Stephanie Merhand, Hiroyuki Murota, Dedee F Murrell, Helen Nankervis, Yukihiro Ohya, Arnold Oranje, Hiromi Otsuka, Carle Paul, Yael Rosenbluth, Hidehisa Saeki, Marie-Louise Schuttelaar, Jean-Francois Stalder, Ake Svensson, Roberto Takaoka, Carl-Fredrik Wahlgren, Stephan Weidinger, Andreas Wollenberg, Hywel Williams.   

Abstract

The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22844983     DOI: 10.1111/j.1398-9995.2012.02874.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  42 in total

1.  [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].

Authors:  E Haufe; S Abraham; A Heratizadeh; I Harder; A Zink; E Weisshaar; A Kleinheinz; R von Kiedrowski; M Worm; M Bell; A Wollenberg; K Neubert; P Staubach-Renz; M Hilgers; T Bieber; I Fell; B Homey; I Effendy; M Mempel; K Schäkel; S Beissert; S Weidinger; T Werfel; J Schmitt
Journal:  Hautarzt       Date:  2018-10       Impact factor: 0.751

2.  The natural history of milk allergy in an observational cohort.

Authors:  Robert A Wood; Scott H Sicherer; Brian P Vickery; Stacie M Jones; Andrew H Liu; David M Fleischer; Alice K Henning; Lloyd Mayer; A Wesley Burks; Alexander Grishin; Donald Stablein; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2012-12-28       Impact factor: 10.793

3.  Interventions to reduce Staphylococcus aureus in the management of eczema.

Authors:  Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-10-29

Review 4.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

Review 5.  Psychological and educational interventions for atopic eczema in children.

Authors:  Steven J Ersser; Fiona Cowdell; Sue Latter; Eric Gardiner; Carsten Flohr; Andrew Robert Thompson; Karina Jackson; Helen Farasat; Fiona Ware; Alison Drury
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

6.  Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials.

Authors:  Bianca Y Kang; Sarah A Ibrahim; Divya Shokeen; Daniel I Schlessinger; Jamie J Kirkham; Jochen Schmitt; Emily Poon; Ian A Maher; Joseph F Sobanko; Todd V Cartee; Murad Alam
Journal:  Arch Dermatol Res       Date:  2021-05-21       Impact factor: 3.017

7.  Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2.

Authors:  A C Fledderus; S G M A Pasmans; A Wolkerstorfer; W Oei; H C Etchevers; M S van Kessel; C M A M van der Horst; P I Spuls
Journal:  Br J Dermatol       Date:  2021-07-14       Impact factor: 11.113

8.  Patient-Reported Outcome Measures in Dermatology: A Systematic Review.

Authors:  Rachael L Pattinson; Nirohshah Trialonis-Suthakharan; Sunnia Gupta; Alasdair L Henry; Jacqueline F Lavallée; Marina Otten; Timothy Pickles; Nick Courtier; Jennifer Austin; Christine Janus; Matthias Augustin; Chris Bundy
Journal:  Acta Derm Venereol       Date:  2021-09-28       Impact factor: 3.875

9.  Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.

Authors:  Uwe Matterne; Merle Margarete Böhmer; Elke Weisshaar; Aldrin Jupiter; Ben Carter; Christian J Apfelbacher
Journal:  Cochrane Database Syst Rev       Date:  2019-01-22

10.  Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.

Authors:  T S Bhat; C M Herbosa; A R Rosenberg; O Sogade; D B Jeffe; N Mehta-Shah; Y R Semenov; A C Musiek
Journal:  Br J Dermatol       Date:  2020-08-02       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.